Peter Hillmen

46.1k total citations · 14 hit papers
346 papers, 22.5k citations indexed

About

Peter Hillmen is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Peter Hillmen has authored 346 papers receiving a total of 22.5k indexed citations (citations by other indexed papers that have themselves been cited), including 271 papers in Genetics, 202 papers in Immunology and 146 papers in Pathology and Forensic Medicine. Recurrent topics in Peter Hillmen's work include Chronic Lymphocytic Leukemia Research (216 papers), Lymphoma Diagnosis and Treatment (146 papers) and Complement system in diseases (119 papers). Peter Hillmen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (216 papers), Lymphoma Diagnosis and Treatment (146 papers) and Complement system in diseases (119 papers). Peter Hillmen collaborates with scholars based in United Kingdom, United States and Italy. Peter Hillmen's co-authors include Russell P. Rother, Stephen J. Richards, Thomas J. Kipps, Monica Bessler, Lucio Luzzatto, Michael Hallek, Emili Montserrat, Andy C. Rawstron, Michael J. Keating and Leonard Bell and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Peter Hillmen

336 papers receiving 22.0k citations

Hit Papers

Guidelines for the diagnosis and treatment of chro... 1995 2026 2005 2015 2008 2005 2018 2006 2002 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
    2008 2.2k citations Peter Hillmen, Michael J. Keating et al. Blood profile →
  2. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
    2005 1.2k citations Russell P. Rother, Peter Hillmen et al. profile →
  3. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
    2018 971 citations Peter Hillmen, Michael J. Keating et al. Blood profile →
  4. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    2006 878 citations Peter Hillmen, Neal S. Young et al. profile →
  5. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    2002 707 citations Michael J. Keating, Peter Hillmen et al. Blood profile →
  6. Natural History of Paroxysmal Nocturnal Hemoglobinuria
    1995 614 citations Peter Hillmen, Monica Bessler et al. profile →
  7. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2018 595 citations Thomas J. Kipps, Barbara Eichhorst et al. profile →
  8. Guidelines for the diagnosis and management of adult aplastic anaemia
    2015 472 citations Sally Killick, Jamie Cavenagh et al. British Journal of Haematology profile →
  9. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2015 420 citations Barbara Eichhorst, Tadeusz Robak et al. profile →
  10. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2020 339 citations Barbara Eichhorst, Tadeusz Robak et al. profile →
  11. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
  12. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
    2019 307 citations Jennifer R. Brown, Susan O’Brien et al. profile →
  13. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    2021 249 citations Peter Hillmen, Jeff Szer et al. profile →
  14. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
    2022 146 citations Paul M. Barr, Carolyn Owen et al. Blood Advances profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Hillmen United Kingdom 64 14.2k 12.1k 9.3k 6.6k 3.9k 346 22.5k
R. Kanti United States 61 16.0k 1.1× 9.0k 0.7× 11.4k 1.2× 2.9k 0.4× 170 0.0× 281 23.3k
Tadeusz Robak Poland 59 10.0k 0.7× 5.3k 0.4× 7.8k 0.8× 5.8k 0.9× 136 0.0× 712 19.3k
Daniel Catovsky United Kingdom 83 19.4k 1.4× 10.3k 0.8× 13.6k 1.5× 14.6k 2.2× 184 0.0× 529 35.2k
William G. Wierda United States 88 18.2k 1.3× 8.2k 0.7× 13.0k 1.4× 11.0k 1.7× 152 0.0× 829 31.7k
Tiziano Barbui Italy 92 16.6k 1.2× 3.0k 0.2× 1.9k 0.2× 17.8k 2.7× 1.4k 0.4× 551 30.4k
Michele Baccarani Italy 80 14.6k 1.0× 3.1k 0.3× 4.5k 0.5× 20.3k 3.1× 227 0.1× 711 29.1k
Emili Montserrat Spain 66 10.5k 0.7× 5.3k 0.4× 9.4k 1.0× 3.8k 0.6× 115 0.0× 296 16.3k
John C. Byrd United States 82 15.1k 1.1× 7.9k 0.7× 10.6k 1.1× 9.3k 1.4× 109 0.0× 701 28.1k
Fernando C. Fervenza United States 67 2.3k 0.2× 3.3k 0.3× 2.4k 0.3× 2.1k 0.3× 9.1k 2.3× 328 14.7k
Stephen M. Ansell United States 83 5.6k 0.4× 8.8k 0.7× 13.8k 1.5× 2.9k 0.4× 216 0.1× 741 26.6k

Countries citing papers authored by Peter Hillmen

Since Specialization
Citations

This map shows the geographic impact of Peter Hillmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hillmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hillmen more than expected).

Fields of papers citing papers by Peter Hillmen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hillmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hillmen. The network helps show where Peter Hillmen may publish in the future.

Co-authorship network of co-authors of Peter Hillmen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hillmen. A scholar is included among the top collaborators of Peter Hillmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hillmen. Peter Hillmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kulasekararaj, Austin, Jamie Cavenagh, Inderjeet Dokal, et al.. (2024). Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British Journal of Haematology. 204(3). 784–804. 35 indexed citations
2.
Latour, Régis Peffault de, Jeff Szer, Ilene C. Weitz, et al.. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. The Lancet Haematology. 9(9). e648–e659. 43 indexed citations
3.
Barr, Paul M., Carolyn Owen, Tadeusz Robak, et al.. (2022). Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia . Blood Advances. 6(11). 3440–3450. 146 indexed citations breakdown →
4.
Linley, Adam J., Annalisa D’Avola, Silvia Cicconi, et al.. (2021). Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. Clinical Cancer Research. 27(20). 5647–5659. 4 indexed citations
5.
Parry, Helen, Graham McIlroy, Rachel Bruton, et al.. (2021). Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer Journal. 11(7). 136–136. 74 indexed citations
6.
Davids, Matthew S., Bryone J. Kuss, Peter Hillmen, et al.. (2020). Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. 26(9). 2096–2103. 33 indexed citations
7.
Danilov, Alexey V., Charles Herbaux, Harriet S. Walter, et al.. (2020). Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(12). 2810–2818. 47 indexed citations
8.
Awan, Farrukh T., Anna Schuh, Jennifer R. Brown, et al.. (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances. 3(9). 1553–1562. 144 indexed citations
9.
Hillmen, Peter, Jennifer R. Brown, John C. Byrd, et al.. (2019). Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 134(Supplement_1). 4307–4307. 2 indexed citations
10.
O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations
11.
Kwok, Marwan, Andy C. Rawstron, Abraham Varghese, et al.. (2016). Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 128(24). 2770–2773. 95 indexed citations
12.
Hill, Anita, Richard Kelly, & Peter Hillmen. (2013). Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 121(25). 4985–4996. 315 indexed citations
13.
14.
Kelly, Richard, Anita Hill, Louise Arnold, et al.. (2011). Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 117(25). 6786–6792. 347 indexed citations
15.
Hillmen, Peter, Aleksander B. Skotnicki, Tadeusz Robak, et al.. (2007). Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 25(35). 5616–5623. 408 indexed citations
16.
Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, et al.. (2007). Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 111(4). 1840–1847. 457 indexed citations
17.
Mould, Diane R., Andreas Baumann, Jens Kuhlmann, et al.. (2007). Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response. British Journal of Clinical Pharmacology. 64(3). 278–291. 92 indexed citations
18.
Hill, Anita, Simon H. Ridley, Dirk Eßer, et al.. (2005). Protection of erythrocytes from human complement–mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood. 107(5). 2131–2137. 44 indexed citations
19.
Hill, Anita, Peter Hillmen, Stephen J. Richards, et al.. (2005). Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 106(7). 2559–2565. 165 indexed citations
20.
Richards, Stephen J., Andy C. Rawstron, & Peter Hillmen. (2000). Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 42(4). 223–233. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Kanti Breakdown of academic impact, for papers by Tadeusz Robak Breakdown of academic impact, for papers by Daniel Catovsky Breakdown of academic impact, for papers by William G. Wierda Breakdown of academic impact, for papers by Tiziano Barbui Breakdown of academic impact, for papers by Michele Baccarani Breakdown of academic impact, for papers by Emili Montserrat Breakdown of academic impact, for papers by John C. Byrd Breakdown of academic impact, for papers by Fernando C. Fervenza Breakdown of academic impact, for papers by Stephen M. Ansell
Rankless by CCL
2026